



**GlaxoSmithKline Pharmaceuticals Ltd.**  
GSK House, Dr. Annie Besant Road, Worli,  
Mumbai - 400 030  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: [www.gsk-india.com](http://www.gsk-india.com)  
Email: [askus@gsk.com](mailto:askus@gsk.com)

1<sup>st</sup> June 2021

To,

**BSE LIMITED**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sirs,

**Sub: Intimation of Record Date pursuant to Regulation 42 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

We wish to inform you that the Company

- Will hold the 96<sup>th</sup> Annual General Meeting ("AGM") on Tuesday, 27<sup>th</sup> July, 2021, through Video Conferencing / Other Audio Visual Means in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India;
- The Board of Directors has recommended a total dividend of Rs 30 per share for the financial year ended 31<sup>st</sup> March, 2021 on Equity Shares of Re.10/- each, subject to the approval of shareholders at the forthcoming Annual General Meeting.
- Has fixed Tuesday, 20<sup>th</sup> July 2021, as the Record Date for determining entitlement of members to final dividend for the financial year ended 31<sup>st</sup> March, 2021. If the final dividend as recommended by the Board of Directors is approved at the AGM, payment of such dividend, subject to deduction of tax at source, will be made on and after Tuesday, 27<sup>th</sup> July 2021 as under:
  - a) To all Beneficial Owners in respect of shares held in dematerialized form as per the data as may be made available by the National Securities Depository Limited and the Central Depository Services (India) Limited as of the close of business hours on Tuesday, 20<sup>th</sup> July 2021.
  - b) To all Members in respect of shares held in physical form after giving effect to valid transmission or transposition requests lodged with the Company as of the close of business hours on Tuesday, 20<sup>th</sup> July 2021.

The above information is also available on the website of the Company.

Kindly take the same on your record.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President – Administration, Real Estate  
& Company Secretary

**Cc:** National Securities Depository Limited  
Central Depository Services (India) Limited  
Kfin Technologies Private Limited

CIN: L24239MH1924PLC001151